DE602006003438D1 - Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen - Google Patents

Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen

Info

Publication number
DE602006003438D1
DE602006003438D1 DE602006003438T DE602006003438T DE602006003438D1 DE 602006003438 D1 DE602006003438 D1 DE 602006003438D1 DE 602006003438 T DE602006003438 T DE 602006003438T DE 602006003438 T DE602006003438 T DE 602006003438T DE 602006003438 D1 DE602006003438 D1 DE 602006003438D1
Authority
DE
Germany
Prior art keywords
medicament
ophthalmic
glycol
poloxamine
adjusting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006003438T
Other languages
German (de)
English (en)
Inventor
Geoffrey Robert Owen
Amy C Brooks
Gustav Graff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE602006003438D1 publication Critical patent/DE602006003438D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602006003438T 2005-05-10 2006-05-08 Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen Active DE602006003438D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67951005P 2005-05-10 2005-05-10
PCT/US2006/017607 WO2006121964A2 (en) 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders

Publications (1)

Publication Number Publication Date
DE602006003438D1 true DE602006003438D1 (de) 2008-12-11

Family

ID=37087751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006003438T Active DE602006003438D1 (de) 2005-05-10 2006-05-08 Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen

Country Status (19)

Country Link
US (1) US20060257486A1 (enExample)
EP (1) EP1906916B1 (enExample)
JP (1) JP4968955B2 (enExample)
KR (1) KR20080011311A (enExample)
CN (1) CN101175476B (enExample)
AT (1) ATE412402T1 (enExample)
AU (1) AU2006244245B2 (enExample)
BR (1) BRPI0608774A2 (enExample)
CA (1) CA2607014A1 (enExample)
CY (1) CY1108676T1 (enExample)
DE (1) DE602006003438D1 (enExample)
DK (1) DK1906916T3 (enExample)
ES (1) ES2313670T3 (enExample)
MX (1) MX2007014084A (enExample)
PL (1) PL1906916T3 (enExample)
PT (1) PT1906916E (enExample)
SI (1) SI1906916T1 (enExample)
WO (1) WO2006121964A2 (enExample)
ZA (1) ZA200709296B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
WO2010101989A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
BRPI1008920A2 (pt) * 2009-03-03 2015-08-25 Alcon Res Ltd Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
KR101809484B1 (ko) * 2009-12-03 2017-12-15 알콘 리서치, 리미티드 카복시비닐 폴리머를 포함하는 나노입자 현탁액
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
EP2609933A4 (en) * 2010-08-27 2014-04-09 Wakamoto Pharma Co Ltd AQUEOUS COMPOSITION FOR ADMINISTRATION
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
CN104706579A (zh) * 2015-03-12 2015-06-17 广州仁恒医药科技有限公司 一种夫西地酸滴眼液及其制备方法
CN111285845B (zh) * 2020-02-11 2021-01-01 深圳厚存纳米药业有限公司 末端官能团化的泊洛沙胺衍生物
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
IL304924A (en) * 2021-02-10 2023-10-01 Iolyx Therapeutics Inc Methods for ophthalmic delivery of roflumilast
WO2023049809A1 (en) 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
KR20250057103A (ko) 2022-09-15 2025-04-28 아큐티스 바이오테라퓨틱스, 인크. 로플루밀라스트 및 많은 양의 약물을 용해시킬 수 있는 용매의 약학 조성물

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
WO1989006130A1 (fr) * 1987-12-25 1989-07-13 Santen Pharmaceutical Co., Ltd. Collyre antiallergique
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5631005A (en) * 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
JP3361106B2 (ja) * 1997-07-29 2003-01-07 アルコン ラボラトリーズ，インコーポレイテッド ハードコンタクトレンズ・ケアのためのコンディショニング溶液
US6037328A (en) * 1998-12-22 2000-03-14 Bausch & Lomb Incorporated Method and composition for rewetting and preventing deposits on contact lens
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1249249A1 (en) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US20020115578A1 (en) * 2000-12-14 2002-08-22 Groemminger Suzanne F. Composition for cleaning and wetting contact lenses
US6646003B2 (en) * 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
JP2003137775A (ja) * 2001-10-31 2003-05-14 Menicon Co Ltd 眼科用組成物
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
EP1487430A4 (en) * 2002-02-28 2007-08-22 Icagen Inc METHOD FOR THE TREATMENT OF DISEASES RELATED TO THE EYE REMINDER
US20040115270A1 (en) * 2002-12-13 2004-06-17 Dharmendra Jani Absorption and controlled release of polyethers from hydrogel biomaterials
JPWO2004084877A1 (ja) * 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders

Also Published As

Publication number Publication date
DK1906916T3 (da) 2009-01-19
CN101175476B (zh) 2011-11-16
ZA200709296B (en) 2009-01-28
AU2006244245B2 (en) 2010-11-18
CN101175476A (zh) 2008-05-07
PT1906916E (pt) 2008-12-10
ATE412402T1 (de) 2008-11-15
CY1108676T1 (el) 2014-04-09
WO2006121964A3 (en) 2007-03-22
CA2607014A1 (en) 2006-11-16
MX2007014084A (es) 2008-02-07
BRPI0608774A2 (pt) 2010-01-26
PL1906916T3 (pl) 2009-02-27
ES2313670T3 (es) 2009-03-01
AU2006244245A1 (en) 2006-11-16
US20060257486A1 (en) 2006-11-16
WO2006121964A2 (en) 2006-11-16
SI1906916T1 (sl) 2009-02-28
JP4968955B2 (ja) 2012-07-04
KR20080011311A (ko) 2008-02-01
JP2008540533A (ja) 2008-11-20
EP1906916B1 (en) 2008-10-29
EP1906916A2 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
DE602006006308D1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
DE602006003438D1 (de) Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
NO20075136L (no) Nye liposompreparater
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
BR0317020A (pt) Derivados de hidroxietilamina para o tratamento de doença de alzheimer
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
BRPI0417476A (pt) derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer
BRPI0510778B8 (pt) composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
ATE425741T1 (de) Arzneizubereitung und deren anwendung zur behandlung von erkrankungen des inneren ohres
UA37620A (uk) Очна мазь
WO2007063428A3 (en) Pharmaceutical compositions comprising carboxyalkylsulfonic acids
ECSP034742A (es) Combinacion de brimonidina y timolol para uso oftalmologico topico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition